Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
about
Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision Cancer MedicineCombating acquired resistance to tyrosine kinase inhibitors in lung cancerA RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressorAZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerIdentification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission TomographyMolecular pathways and therapeutic targets in lung cancerThe NF1 somatic mutational landscape in sporadic human cancers.The NF1 gene revisited - from bench to bedside.Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer.Isolation of epithelial, endothelial, and immune cells from lungs of transgenic mice with oncogene-induced lung adenocarcinomasLung cancer in the era of precision medicineLoss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma.The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.Mechanisms of resistance to EGFR tyrosine kinase inhibitors.The prognostic and predictive value of solid subtype in invasive lung adenocarcinoma.Using a biologically annotated library to analyze the anticancer mechanism of serine palmitoyl transferase (SPT) inhibitors.Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Drug Resistance to EGFR Inhibitors in Lung CancerIntegrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutationHow to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.Decreased glutathione biosynthesis contributes to EGFR T790M-driven erlotinib resistance in non-small cell lung cancer.Resisting Resistance: Targeted Therapies in Lung Cancer.Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.Reading between the lines; understanding drug response in the post genomic era.Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.A genetic interaction analysis identifies cancer drivers that modify EGFR dependency.EGFR-Stat3 signalling in nerve glial cells modifies neurofibroma initiation.Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer.Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models.The role of the NORE1A tumor suppressor in Oncogene-Induced Senescence.RAS Proteins and Their Regulators in Human Disease.NORE1A Regulates MDM2 Via β-TrCP.Understanding and targeting resistance mechanisms in NSCLC.Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer.Neurofibromatosis type-1 is a prognostic indicator in human gastric carcinoma.ER stress signaling promotes the survival of cancer 'persister cells' tolerant to EGFR tyrosine kinase inhibitors.An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
P2860
Q26800337-3C40867E-E902-4F80-A859-7BF3C083C670Q26824877-77FD296C-B806-414C-8201-4B907CEB576BQ27003534-7455D758-2F4B-40A4-9B31-DB0056F5C49EQ27853013-6C03E031-AA0D-4DBE-B384-21511EE1DD1EQ28553692-51791A52-56BE-4764-A248-34C96E2165F3Q33688872-F50627ED-55AE-40E1-8DFC-81A85C9D16D7Q33823452-0C1BD922-2DAC-403F-8E9E-7F52AC63BE7BQ34227509-CDA4218E-525A-41E7-A344-7A10DFA9A7E5Q35112467-8BCEB01C-4E32-42C3-BC8C-B0EA6FAA7860Q35816386-DFA82AF6-4FCF-4070-B3DE-2682A580ED02Q35861107-0523F27B-0AA3-4D63-9E49-558E9B13F3BFQ36028210-987AEF72-7599-46CB-B3C0-5530D55AA252Q36104980-1B8266C0-090B-4182-947F-C6549365B9C0Q36238664-3B1694B9-38E9-4239-95F2-1DB78E3B4B9CQ36294486-6999457C-65E8-4ADF-9BBA-72B1B9C8304FQ36342704-C028BE9E-D026-4D4A-8433-3551021E495AQ36775204-9378516A-884B-4595-8569-7EA8D739B770Q36834883-F5C95D59-97A9-4E57-9D49-CF11946E4759Q37046462-DED2608F-6311-4678-A162-0FD0EECB77CCQ37113976-86C44BD8-2CDA-4432-AECC-566923E5748BQ37285973-DC2BF5E2-2E33-414C-88AE-9B972DB5891AQ37388238-02BD16B4-45BC-448B-9594-1667F45C5055Q37455251-9C7D1356-C0F0-401A-8530-49AB95642207Q37618018-D27176BB-8708-4F73-AE98-ED8D7080EE03Q38222600-CDE1121C-EBB3-4BB8-BE75-6AAB1C828655Q38258948-3100E2D4-C8BA-4074-B336-0914B6E3E50EQ38390205-469A7543-CCF2-46CF-A9D1-03810123A889Q38717620-5D92B132-AF2A-4234-8D94-FD6870DA9232Q38740814-2DDBD110-8CE5-47C3-A01A-371C5DB633CDQ38868047-862A2C1C-97BA-4D2F-8806-33077B9DA473Q38881938-AC8E0689-564E-412D-80FD-E9E22F347EA3Q38887681-0B141BB6-EC6E-4E9F-AB20-24B699CA52FFQ39271171-2F320AA4-34AA-4B4A-9068-DACA48DF4756Q39407402-C84A090F-FE77-46A2-BCC6-118836234399Q40681916-A20B0CF2-1F0A-4761-BFC4-FAC31EAEF7E4Q46915997-A3B597E5-4871-4216-9F15-464E27FBB744Q47146662-1222672F-3FF7-4BB2-93B1-D220B073137CQ47172712-3592075B-ED17-4CB2-B3FC-4BE60B767220Q47273602-891CF033-5B7E-4380-9458-FF25FE08CF57Q48165470-F0399F9E-13EE-4A7C-A626-1D5A45E59037
P2860
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@ast
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@en
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
@nl
type
label
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@ast
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@en
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
@nl
prefLabel
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@ast
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@en
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer.
@nl
P2093
P2860
P50
P1433
P1476
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer
@en
P2093
Almudena García-Castaño
Anna Wurtz
Catherine Cowell
Daniëlle A M Heideman
Egbert F Smit
Elza C de Bruin
Guus J Heynen
Javier Gómez-Román
Julian Downward
Ming Jiang
P2860
P304
P356
10.1158/2159-8290.CD-13-0741
P577
2014-02-17T00:00:00Z